Atavistik Bio
atavistikbio.com
Actively hiring
Drug Discovery
Prescription Drugs
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$180M
2 rounds on record
Latest round
$120M
Series B · Dec 2025 · 9 mo ago
Team
35
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Backers
2
RA Capital Management, Nextech Invest
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Dec 2025 | $120M | — | manilatimes.net |
| Series A | Aug 2021 | $60M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
Nextech Invest Similar startupsby what they do, their industry and backers
LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages…
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
Kymera is inventing a new generation of small molecule medicines by tackling the root cause of disease with targeted protein degradation.
Our team has extensive expertise in kidney disease, targeted delivery of RNA therapeutics, translational systems biology and data sciences…
Relay Therapeutics® puts protein motion at the heart of drug discovery to dramatically expand therapeutic possibilities.
Iambic Therapeutics is a clinical-stage biotechnology company headquartered in San Diego, California, that uses physics-informed artificial…
News
Roundup: Nanexa, Earendil Labs, and Atavistik Bio Enter Platform Deals with Novo Nordisk, Genentech, and Roche PharmExec
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Read more
Report
Atavistik Bio, Roche Partner To Develop Novel Therapies For Cardiometabolic Diseases
Atavistik Bio, a clinical-stage biotechnology company focused on discovering new medicines through its proprietary allosteric drug discovery platform has entered into a strategic research collaboration with Roche (RHHBY) to identify and develop novel smal
Read more
Report
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
Collaboration leverages Atavistik Bio's proprietary AMPSTM platform to identify and advance novel allosteric small molecules against multiple targ...
Read more
Report
Atavistik Bio, Inc. and Roche Announce Strategic Research Collaboration to Discover and Develop Novel Allosteric Therapeutics
Read more
Report
Atavistik Bio partners with Cure HHT Clinical Trial Network to advance development of ATV-1601 for hereditary haemorrhagic telangiectasia
Atavistik Bio partners with Cure HHT Clinical Trial Network to advance development of ATV-1601 for hereditary haemorrhagic telangiectasia
Read more
Report
Pro access
Upgrade to see all 14 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
50-200 est. staff
Financials
Total raised
$180M
Latest round
Series B
Funding rounds
2
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2025 | $120M | |
| Series A | 2021 | $60M | Details |